Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mezagitamab + pomalidomide + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (mezagitamab), Oral (pomalidomide), Oral (dexamethasone)
01
Overview
**Mezagitamab + pomalidomide + dexamethasone** is an investigational combination regimen studied for relapsed/refractory multiple myeloma. Mezagitamab is a subcutaneously administered human IgG1 anti-CD38 monoclonal antibody designed to target the CD38 receptor on plasma cells, directly inducing cytotoxicity and antibody-dependent cellular cytotoxicity. Pomalidomide is an oral immunomodulatory agent that enhances immune cell activity against myeloma and has antineoplastic effects. Dexamethasone is a synthetic glucocorticoid used to reduce inflammation and suppress immune responses. This combination aims to produce synergistic antimyeloma activity by targeting malignant plasma cells through complementary mechanisms. The combination has been tested in phase 1b trials in heavily pretreated myeloma patients and showed a tolerable safety profile, but the further development of mezagitamab in myeloma is not planned. Mezagitamab is currently under investigation for autoimmune diseases[6][8].
- Brand names
- Pomalyst (for pomalidomide)
02
Targets
CD38 (Cluster of Differentiation 38)CRBN (Cereblon)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on mezagitamab + pomalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mezagitamab + pomalidomide + dexamethasone.